-
1دورية أكاديمية
المؤلفون: SPRYNGER, Muriel, LANCELLOTTI, Patrizio
المصدر: Revue Médicale de Liège, 75 (5-6), 310-315 (2020-05)
مصطلحات موضوعية: Anticoagulants, Administration, Oral, Anticoagulants/administration & dosage, Atrial Fibrillation, Humans, Venous Thromboembolism, Antagonists, Atrial fibrillation, Heparin, Venous thromboembolic disease, Vitamin K, Direct oral anticoagulants, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire
Relation: urn:issn:0370-629X; urn:issn:2566-1566
URL الوصول: https://orbi.uliege.be/handle/2268/292603
-
2دورية أكاديمية
المصدر: Revue Médicale de Liège, 75 (4), 203-209 (2020)
مصطلحات موضوعية: Anticoagulants/administration & dosage, Drug Administration Schedule, Humans, Recurrence, Risk Factors, Time Factors, Venous Thromboembolism, Venous Thrombosis/drug therapy, Anticoagulant, Anticoagulation duration, Bleeding risk, Risk of recurrence, Venous thrombosis, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire
Relation: urn:issn:0370-629X; urn:issn:2566-1566
URL الوصول: https://orbi.uliege.be/handle/2268/249468
-
3كتاب
المؤلفون: Fahlén, Martin
المساهمون: Odén, Anders, Spri
مصطلحات موضوعية: Anticoagulants: administration & dosage, Therapy, computer- assisted
-
4
المؤلفون: Själander, Anders, Johansson, Lars, Hillarp, Andreas, Bergqvist, David, Tengborn, Lilian, Svensson, Peter
المصدر: Lakartidningen. 106(10):5-682
مصطلحات موضوعية: Anticoagulants/administration & dosage, Arthroplasty, Replacement, Knee/adverse effects, Dalteparin/administration & dosage, Diagnosis, Differential, Female, Fibrinolytic Agents/administration & dosage, Heparin/administration & dosage, Humans, Middle Aged, Platelet Count, Postoperative Complications/etiology, Risk Factors, Thrombocytopenia/chemically induced, Thrombosis/etiology, Medicin och hälsovetenskap, Klinisk medicin, Hematologi, Medical and Health Sciences, Clinical Medicine, Hematology
URL الوصول: https://lup.lub.lu.se/record/d3701302-4486-42fa-85c7-ff1da704b67e
https://lakartidningen.se/wp-content/uploads/OldWebArticlePdf/1/11511/LKT0910s682_685.pdf -
5
المؤلفون: Norrving, Bo
المصدر: Läkartidningen. 99(20):9-2298
مصطلحات موضوعية: Anticoagulants : administration & dosage, Cerebral Infarction : prevention & control, Cerebrovascular Accident : prevention & control, Comparative Study, Fibrinolytic Agents : administration & dosage, Human, International Normalized Ratio, Randomized Controlled Trials, Multicenter Studies, Warfarin : administration & dosage, Aspirin : administration & dosage, Recurrence : prevention & control, Medicin och hälsovetenskap, Klinisk medicin, Neurologi, Medical and Health Sciences, Clinical Medicine, Neurology
-
6
المؤلفون: Goligher, Ewan C, Bradbury, Charlotte A, McVerry, Bryan J, Lawler, Patrick R, Berger, Jeffrey S, Gong, Michelle N, Carrier, Marc, Reynolds, Harmony R, Kumar, Anand, Turgeon, Alexis F, Kornblith, Lucy Z, Kahn, Susan R, Marshall, John C, Kim, Keri S, Houston, Brett L, Derde, Lennie PG, Cushman, Mary, Tritschler, Tobias, Angus, Derek C, Godoy, Lucas C, McQuilten, Zoe, Kirwan, Bridget-Anne, Farkouh, Michael E, Brooks, Maria M, Lewis, Roger J, Berry, Lindsay R, Lorenzi, Elizabeth, Gordon, Anthony C, Berry, Scott M, McArthur, Colin J, Neal, Matthew D, Hochman, Judith S, Webb, Steven A, Zarychanski, Ryan, Ahuja, Tania, Al-Beidh, Farah, Annane, Djillali, Arabi, Yaseen M, Aryal, Diptesh, Kreuziger, Lisa Baumann, Beane, Abi, Bhimani, Zahra, Bihari, Shailesh, Billett, Henny H, Bond, Lindsay, Bonten, Marc, Brunkhorst, Frank, Buxton, Meredith, Buzgau, Adrian, Castellucci, Lana A, Chekuri, Sweta, Chen, Jen-Ting, Cheng, Allen C, Chkhikvadze, Tamta, Coiffard, Benjamin, Contreras, Aira, Costantini, Todd W, de Brouwer, Sophie, Detry, Michelle A, Duggal, Abhijit, Dzavik, Vladimir, Effron, Mark B, Eng, Heather F, Escobedo, Jorge, Estcourt, Lise J, Everett, Brendan M, Fergusson, Dean A, Fitzgerald, Mark, Fowler, Robert A, Froess, Joshua D, Fu, Zhuxuan, Galanaud, Jean P, Galen, Benjamin T, Gandotra, Sheetal, Girard, Timothy D, Goodman, Andrew L, Goossens, Herman, Green, Cameron, Greenstein, Yonatan Y, Gross, Peter L, Haniffa, Rashan, Hegde, Sheila M, Hendrickson, Carolyn M, Higgins, Alisa M, Hindenburg, Alexander A, Hope, Aluko A, Horowitz, James M, Horvat, Christopher M, Huang, David T, Hudock, Kristin, Hunt, Beverley J, Husain, Mansoor, Hyzy, Robert C, Jacobson, Jeffrey R, Jayakumar, Devachandran, Keller, Norma M, Khan, Akram, Kim, Yuri, Kindzelski, Andrei, King, Andrew J, Kornblith, Aaron E, Kutcher, Matthew E, Laffan, Michael A, Lamontagne, Francois, Le Gal, Gregoire, Leeper, Christine M, Leifer, Eric S, Lim, George, Lima, Felipe Gallego, Linstrum, Kelsey, Litton, Edward, Lopez-Sendon, Jose, Lother, Sylvain A, Marten, Nicole, Marinez, Andrea Saud, Martinez, Mary, Garcia, Eduardo Mateos, Mavromichalis, Stavroula, McAuley, Daniel F, McDonald, Emily G, McGlothlin, Anna, McGuinness, Shay P, Middeldorp, Saskia, Montgomery, Stephanie K, Mouncey, Paul R, Murthy, Srinivas, Nair, Girish B, Nair, Rahul, Nichol, Alistair D, Nicolau, Jose C, Nunez-Garcia, Brenda, Park, John J, Park, Pauline K, Parke, Rachael L, Parker, Jane C, Parnia, Sam, Paul, Jonathan D, Pompilio, Mauricio, Quigley, John G, Rosenson, Robert S, Rost, Natalia S, Rowan, Kathryn, Santos, Fernanda O, Santos, Marlene, Santos, Mayler O, Satterwhite, Lewis, Saunders, Christina T, Schreiber, Jake, Schutgens, Roger EG, Seymour, Christopher W, Siegal, Deborah M, Silva, Delcio G, Singhal, Aneesh B, Slutsky, Arthur S, Solvason, Dayna, Turner, Anne M, Van Bentum-Puijk, Wilma, van de Veerdonk, Frank L, van Diepen, Sean, Vazquez-Grande, Gloria, Wahid, Lana, Wareham, Vanessa, Widmer, R Jay, Wilson, Jennifer G, Yuriditsky, Eugene, Zhong, Yongqi, Investigators, REMAP-CAP, Investigators, ACTIV-4a, Investigators, ATTACC
المساهمون: NIHR, National Institute for Health Research, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), National Institutes of Health, NIH: 1OT2HL156812-01, AR7-162822, OTA-20-011, RP-2015-06-18, National Heart, Lung, and Blood Institute, NHLBI, Amgen, CancerCare Manitoba Foundation, CCMF, University of Manitoba, UM, Health Research Board, HRB: CTN 2014-012, Canadian Institutes of Health Research, CIHR: 158584, 447335, COVID-19, National Institute for Health Research, NIHR, European Commission, EC: 602525, FP7-HEALTH-2013-INNOVATION, National Health and Medical Research Council, NHMRC: APP1101719, APP1116530, Health Research Council of New Zealand, HRC: 16/631, Eisai, Ministère des Affaires Sociales et de la Santé: PHRC-20-0147, Université Pierre et Marie Curie, UPMC, Horizon 2020: 101003589, NIHR Imperial Biomedical Research Centre, BRC, Minderoo Foundation, REMAP-CAP was supported by the European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (grant 602525) and the Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (grant 101003589) and by grants from the Australian National Health and Medical Research Council (APP1101719 and APP1116530), the Health Research Council of New Zealand (16/631), the Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant 158584 and COVID-19 Rapid Research Operating Grant 447335), the U.K. National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). The ATTACC platform was supported by grants from the Canadian Institutes of Health Research, LifeArc, Thistledown Foundation, Research Manitoba, CancerCare Manitoba Foundation, Victoria General Hospital Foundation, Ontario Ministry of Health, and the Peter Munk Cardiac Centre. The ACTIV-4a platform was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and administered through OTA-20-011 and was supported in part by NIH agreement 1OT2HL156812-01. Dr. Goligher is the recipient of an Early Career Investigator award from the Canadian Institutes of Health Research (grant AR7-162822). Dr. Gordon is funded by an NIHR Research Professorship (RP-2015-06-18). Dr. Turgeon is funded by a Canada Research Chair-Tier 2. Dr. Zarychanski is the recipient of the Lyonel G. Israels Research Chair in Hematology (University of Manitoba)., Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, Investigators, REMAP-CAP, Investigators, ACTIV-4a, Investigators, ATTACC, REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators
المصدر: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (9), pp.777-789. ⟨10.1056/NEJMoa2103417⟩
New England journal of medicine, 385(9), 777-789. Massachussetts Medical Society
et al. 2021, ' Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 ', New England Journal of Medicine, vol. 385, no. 9, pp. 777-789 . https://doi.org/10.1056/NEJMoa2103417
NEW ENGLAND JOURNAL OF MEDICINE
The New England Journal of Medicine, 385, 9, pp. 777-789
Investigators, REMAP-CAP & Dark, P 2021, ' Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 ', The New England Journal of Medicine, vol. 385, no. 9, pp. 777-789 . https://doi.org/10.1056/NEJMoa2103417
The New England Journal of Medicine, 385, 777-789
The New England journal of medicineمصطلحات موضوعية: Male, covid-19, anticoagulation, adaptive platform trial, [SDV]Life Sciences [q-bio], Critical Illness, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Hemorrhage, 030204 cardiovascular system & hematology, heparin, COVID-19/drug therapy, 03 medical and health sciences, 0302 clinical medicine, Medicine, General & Internal, Hemorrhage/chemically induced, General & Internal Medicine, Odds Ratio, thrombosis, covid-19, Humans, 030212 general & internal medicine, Hospital Mortality, Treatment Failure, Heparin/administration & dosage, anticoagulation, 11 Medical and Health Sciences, Aged, Anticoagulants/administration & dosage, Science & Technology, Thrombosis/prevention & control, Heparin, low molecular weight heparin, Anticoagulants, COVID-19, Thrombosis, General Medicine, Middle Aged, Respiration, Artificial, 3. Good health, COVID-19 Drug Treatment, critical care, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Logistic Models, ACTIV-4a Investigators, Female, Human medicine, ATTACC Investigators, REMAP-CAP Investigators, Covid-19, Life Sciences & Biomedicine
وصف الملف: application/pdf
-
7رسالة جامعية
المؤلفون: Grzymala-Lubanski, Bartosz
المساهمون: Umeå universitet. Institutionen för folkhälsa och klinisk medicin
مصطلحات موضوعية: Mechanical heart valve, Anticoagulation, Warfarin, Time in Therapeutic Range (TTR), INR variability, Anticoagulants -- therapeutic use, Anticoagulants -- administration & dosage, Heart valve prosthesis -- adverse effects, Warfarin -- therapeutic use, Warfarin -- administration & dosage, Algorithms, Atrial fibrillation -- drug therapy, Drug therapy, computer-assisted -- methods, Registries, Blood coagulation -- drug effects, Stroke -- prevention & control, Venous thromboembolism -- drug therapy, Venous thromboembolism -- prevention & control
Degree: Diss. (sammanfattning) Umeå : Umeå universitet, 2017
-
8رسالة جامعية
المؤلفون: Själander, Sara
المساهمون: Umeå universitet. Institutionen för folkhälsa och klinisk medicin
مصطلحات موضوعية: Oral anticoagulation, Haemorrhage, Electrical cardioversion, Pulmonary vein isolation, Aspirin -- therapeutic use, Atrial fibrillation -- drug therapy, Brain ischemia -- prevention & control, Platelet aggregation inhibitors -- therapeutic use, Registries, Stroke -- prevention & control, Thromboembolism -- prevention & control, Algorithms, Anticoagulants -- administration & dosage, Drug therapy, computer-assisted -- methods, Warfarin -- administration & dosage
Degree: Diss. (sammanfattning) Umeå : Umeå universitet, 2016
-
9دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
10
المؤلفون: Stefan Agewall, Jesper K. Jensen, Thomas G. von Lueder, Ingrid Hopper, Dipak Kotecha, Dan Atar, Moo Hyun Kim, Victor L. Serebruany, Robert J. Mentz
المصدر: von Lueder, T G, Atar, D, Agewall, S, Jensen, J K, Hopper, I, Kotecha, D, Mentz, R J, Kim, M H & Serebruany, V L 2019, ' All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System ', American Journal of Therapeutics, vol. 26, no. 6, pp. e671-e678 . https://doi.org/10.1097/MJT.0000000000000883
مصطلحات موضوعية: Male, medicine.medical_specialty, Vitamin K, medicine.drug_class, Myocardial Infarction, Administration, Oral, 030204 cardiovascular system & hematology, Warfarin/adverse effects, Dabigatran, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Edoxaban, Internal medicine, medicine, Adverse Drug Reaction Reporting Systems, Humans, Pharmacology (medical), Vitamin K/antagonists & inhibitors, cardiovascular diseases, 030212 general & internal medicine, Stroke, Heart Failure, Anticoagulants/administration & dosage, Pharmacology, Rivaroxaban, Myocardial Infarction/complications, United States Food and Drug Administration, business.industry, Anticoagulant, Warfarin, Anticoagulants, General Medicine, United States/epidemiology, medicine.disease, Adverse Drug Reaction Reporting Systems/statistics & numerical data, United States, Treatment Outcome, Heart Failure/complications, chemistry, Cardiology, Myocardial infarction complications, Female, Apixaban, business, Stroke/complications, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b600a199dfd787497131ceec46f9df99
https://doi.org/10.1097/mjt.0000000000000883